In the United Kingdom, the use of weight-loss medications has become as widespread in households as vegetarian or pescatarian diets, data shows. Among the country’s 29 million households, approximately 8.5 percent include at least one individual using appetite-suppressing drugs such as Mounjaro and Wegovy, surpassing the prevalence of vegetarian (5.5 percent) and pescatarian (3 percent) households.

These medications belong to a class known as GLP-1 receptor agonists, which mimic natural gut hormones to promote feelings of fullness and reduce appetite. Initially available primarily as injections, their popularity increased significantly following regulatory approval of oral formulations in June. The rapid uptake has led market analysts to anticipate that by next year, weight-loss drug users could be present in 10 percent of UK households.

Market research firm Worldpanel, which analyzed data from over 9,600 households, noted that the incidence of these drugs is approaching the level of households purchasing Kellogg’s Rice Krispies cereal, which appears in 8.6 percent of homes. The firm also observed that households with GLP-1 users have reduced their annual grocery expenditure by an estimated £1 billion collectively.

In addition to cutting down on food spending, particularly on alcohol and crisps—down 15 percent more in GLP-1 households compared to others—these households have increased spending on health, beauty, and apparel. Within the first year of starting the medication, GLP-1 users spent £78 million more than anticipated on health and beauty products, while nearly 30 percent reported increased expenditure on clothing and footwear.

The demographic profile of users is also shifting. Since February, the number of men using these drugs has nearly doubled, rising from 440,000 to 830,000, reflecting a growing appeal across genders. Nishita Pattni, a senior consultant at Worldpanel, commented that this trend is expected to continue gaining momentum.

The data illustrates a significant change in consumer behavior linked to the rising popularity of weight-loss medications, with potential implications for food and retail sectors in the UK.